FDA Designates Washington University’s WU-CART-007 as Breakthrough Therapy for T-Cell Malignancies: Allogeneic Anti-CD7 CAR T-Cell Therapy Achieves 73% Complete Remission

August 17, 2026

Siteman Cancer Center at Barnes-Jewish Hospital and WashU Medicine USA

Overview

The FDA has granted Breakthrough Therapy Designation (BTD) to WU-CART-007, an allogeneic anti-CD7 CAR T-cell therapy developed by Washington University School of Medicine researchers, for adult and adolescent patients with relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma (T-ALL/LBL). Early global trials demonstrated remarkable results, with 73% of treated patients achieving complete remission, positioning this therapy as a potential game-changer for T-cell malignancies. This designation is expected to accelerate the drug’s development and review process.

In Depth

Background

T-cell malignancies have historically presented significant challenges for CAR T-cell therapy development compared to B-cell malignancies. A primary obstacle has been the expression of target T-cell antigens on the CAR T-cells themselves, leading to issues such as “T-cell fratricide” or “CAR T-cell alloreactivity,” where the therapeutic cells attack each other.

Key Findings

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to WU-CART-007, an allogeneic anti-CD7 CAR T-cell therapy developed by researchers at Washington University School of Medicine. This designation is for adult and adolescent patients with relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL). In initial global trials, this therapy demonstrated a remarkable 73% complete remission (CR) rate, signaling its potential to revolutionize the treatment of T-cell malignancies.

Technical and Clinical Details

WU-CART-007 distinguishes itself from existing autologous CAR T-cell therapies by utilizing allogeneic (donor-derived) CAR T-cells. Traditional CAR T-cell therapies, which use a patient’s own T-cells, often require lengthy manufacturing times and may be challenging to apply in patients with rapidly progressing disease. WU-CART-007 involves genetically modifying T-cells harvested from a healthy donor to express a Chimeric Antigen Receptor (CAR) that targets the CD7 antigen, found on cancer cells. Crucially, the therapy incorporates gene-editing techniques to modify specific genes within the donor T-cells, thereby minimizing the risk of Graft-versus-Host Disease (GVHD). Early clinical trials reported that 73% of relapsed or refractory T-ALL/LBL patients treated with WU-CART-007 achieved complete remission, with many patients experiencing full disease control. This represents an unprecedented therapeutic efficacy in an area where treatment options for T-cell malignancies are severely limited.

Industry Context and Significance

WU-CART-007 has overcome these challenges by combining high specificity for the CD7 antigen with gene-editing technology designed to prevent T-cell fratricide. Breakthrough Therapy Designation (BTD) is awarded to drugs that offer a new treatment for a serious condition and demonstrate the potential for substantial clinical improvement over available therapies, accelerating the FDA’s review process. This designation underscores the high probability that WU-CART-007 could fundamentally transform the treatment landscape for T-cell malignancies.

Future Outlook

The BTD for WU-CART-007 marks a critical step toward making this groundbreaking CAR T-cell therapy available to patients sooner. While its safety and efficacy will undergo further validation through larger-scale clinical trials, its initial success broadens the potential of allogeneic CAR T-cell therapies and offers hope to a greater number of cancer patients. This technology may also pave the way for the development of allogeneic cell therapies for other autoimmune diseases and solid tumors, beyond T-cell malignancies. The global medical community keenly awaits the progress of its ongoing clinical development.

Source: https://siteman.washu.edu/fda-grants-breakthrough-therapy-designation-to-treatment-for-rare-blood-cancers/

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.